TY - JOUR
T1 - Academic discovery of anticancer drugs
T2 - Historic and future perspectives
AU - Carugo, Alessandro
AU - Draetta, Giulio F.
N1 - Publisher Copyright:
© 2019 by Annual Reviews. All rights reserved.
PY - 2019
Y1 - 2019
N2 - The identification and prosecution of meritorious anticancer drug targets and the discovery of clinical candidates represent an extraordinarily time- and resource-intensive process, and the current failure rate of late-stage drugs is a critical issue that must be addressed. Relationships between academia and industry in drug discovery and development have continued to change over time as a result of technical and financial challenges and, most importantly, to the objective of translating impactful scientific discoveries into clinical opportunities. This Golden Age of anticancer drug discovery features an increased appreciation for the high-risk, high-innovation research conducted in the nonprofit sector, with the goals of infusing commercial drug development with intellectual capital and curating portfolios that are financially tenable and clinically meaningful. In this review, we discuss the history of academic-industry interactions in the context of antidrug discovery and offer a view of where these interactions are likely headed as we continue to reach new horizons in our understanding of the immense complexities of cancer biology.
AB - The identification and prosecution of meritorious anticancer drug targets and the discovery of clinical candidates represent an extraordinarily time- and resource-intensive process, and the current failure rate of late-stage drugs is a critical issue that must be addressed. Relationships between academia and industry in drug discovery and development have continued to change over time as a result of technical and financial challenges and, most importantly, to the objective of translating impactful scientific discoveries into clinical opportunities. This Golden Age of anticancer drug discovery features an increased appreciation for the high-risk, high-innovation research conducted in the nonprofit sector, with the goals of infusing commercial drug development with intellectual capital and curating portfolios that are financially tenable and clinically meaningful. In this review, we discuss the history of academic-industry interactions in the context of antidrug discovery and offer a view of where these interactions are likely headed as we continue to reach new horizons in our understanding of the immense complexities of cancer biology.
KW - academic-industry partnering
KW - cancer biology
KW - cancer therapeutics
KW - disruptive technologies
KW - oncology drug discovery
UR - http://www.scopus.com/inward/record.url?scp=85083451600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083451600&partnerID=8YFLogxK
U2 - 10.1146/annurev-cancerbio-030518-055645
DO - 10.1146/annurev-cancerbio-030518-055645
M3 - Review article
AN - SCOPUS:85083451600
SN - 2472-3428
VL - 3
SP - 385
EP - 408
JO - Annual Review of Cancer Biology
JF - Annual Review of Cancer Biology
IS - 1
ER -